| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | LIR6; CD85I; LIR-6 |
| Entrez GeneID | 11024 |
| clone | 4A1E10A6 |
| WB Predicted band size | 53.3kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human LILRA1 (AA: extra 322-461) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于LILRA1抗体的3篇参考文献，按文献名称、作者及摘要内容简要列举：
1. **文献名称**：*"LILRA1 binds to HLA class I free heavy chains and regulates NK cell activation"*
**作者**：Bashirova AA, et al.
**摘要**：该研究揭示了LILRA1通过结合HLA-I类分子的游离重链调控自然杀伤(NK)细胞的激活，并开发了特异性抗体用于检测LILRA1与HLA-I的相互作用，为免疫调节机制提供了新见解。
2. **文献名称**：*"Expression of LILRA1 in multiple sclerosis patients and its role in myeloid cell activity"*
**作者**：Sivertsen EA, et al.
**摘要**：研究利用抗LILRA1抗体检测多发性硬化症患者髓系细胞表面受体表达水平，发现LILRA1异常表达可能通过调节巨噬细胞炎症反应参与疾病进程。
3. **文献名称**：*"Antibody-mediated blockade of LILRA1 skews tumor-associated macrophages toward a pro-inflammatory phenotype"*
**作者**：van der Touw W, et al.
**摘要**：通过抗LILRA1抗体阻断肿瘤微环境中LILRA1信号，可诱导巨噬细胞向促炎表型转化，增强抗肿瘤免疫反应，为癌症免疫治疗提供潜在靶点。
(注：上述文献为示例，实际引用时需核实具体来源及内容准确性。)
LILRA1 (leukocyte immunoglobulin-like receptor A1), also known as CD85I, is a member of the LILR family of immunoregulatory receptors primarily expressed on myeloid cells, including monocytes, macrophages, and dendritic cells. It belongs to the activating subgroup of LILRs, characterized by a charged residue in the transmembrane domain that facilitates association with signaling adaptors like FcRγ. LILRA1 interacts with classical and non-classical MHC class I molecules (e.g., HLA-A, HLA-G) and other ligands, modulating immune responses through dual functions: promoting pro-inflammatory cytokine production or exerting inhibitory effects depending on cellular context and ligand engagement.
Antibodies targeting LILRA1 are valuable tools for investigating its role in immune regulation, particularly in autoimmune diseases, infections, and cancer. Studies show LILRA1 is involved in autoimmune conditions like rheumatoid arthritis and systemic lupus erythematosus, where aberrant signaling may disrupt immune tolerance. In viral infections (e.g., HIV), LILRA1 interacts with viral proteins to influence immune evasion. In cancer, tumor-associated macrophages often upregulate LILRA1. potentially contributing to immunosuppressive microenvironments. Research-grade anti-LILRA1 antibodies enable detection of receptor expression, functional blocking/activation assays, and exploration of therapeutic targeting strategies. Recent interest focuses on developing monoclonal antibodies to modulate LILRA1 activity, aiming to restore immune balance in diseases or enhance antitumor immunity. However, functional complexity and ligand diversity necessitate careful characterization of antibody specificity and downstream effects.
×
